Efficacy and Tolerance of a Derivative of Salicylic Acid and 5% Benzoyl Peroxide in Facial Acne Vulgaris
Information source: Cosmetique Active International
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acne Vulgaris
Intervention: Lipo Hydroxy Acid (Drug); 5% benzoyl peroxide gel (Drug)
Phase: N/A
Status: Completed
Sponsored by: Cosmetique Active International Official(s) and/or principal investigator(s): Robert Bissonnette, MD, Principal Investigator, Affiliation: Innovaderm Research
Summary
Acne vulgaris is a frequent inflammatory skin condition involving the pilosebaceous unit and
affecting more than 80% of teenagers. Mild to moderate acne vulgaris is usually treated with
topical agents such as benzoyl peroxide, retinoids and antibiotics. These treatments can be
associated with local tolerance problems and/or antibiotic resistance. Salicylic acid has
been shown to be an effective treatment for acne. LHA is a lipophilic hydroxy acid
derivative of salicylic acid that has comedolytic and antibacterial properties.
The objective of this trial was to compare the efficacy and tolerance of a cream formulation
containing 0. 3% LHA (LHA formulation) to a 5% benzoyl peroxide gel.
Clinical Details
Official title: Randomized Study Comparing the Efficacy and Tolerance of a Lipophilic Hydroxy Acid Derivative of Salicylic Acid and 5% Benzoyl Peroxide in the Treatment of Facial Acne Vulgaris
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Reduction in inflammatory lesions
Secondary outcome: Reduction in non-inflammatory lesionsOverall efficacy Overall tolerance Evaluation of pruritus, burning and tingling by the subject Evaluation of erythema and desquamation by the blind assessor
Detailed description:
This was a randomized clinical trial performed at two centers (Montreal and Laval, Quebec,
Canada) under the direction of the same principal investigator. Eighty (80) subjects were
enrolled in the study. Subjects were asked to report to the clinic for four visits (D0, D28,
D56, D87). The LHA formulation was applied twice a day (morning and evening) and benzoyl
peroxide was applied daily (evening) on a clean face for a total of 12 weeks.
Efficacy was evaluated at day 28, 56 and 87. The number of papules, pustules, opened and
closed comedones were counted at each visit by a blinded assessor. The overall efficacy was
evaluated with a 4-point scale (no improvement, moderate, good and excellent) by the subject
and the blinded assessor. Clinical examination included evaluation of sensitivity of the
skin (presence of erythema and desquamation) by the investigator and of pruritus, tingling
and burning sensation by subjects on a 4-point scale. Finally, the subject and the skin
assessor both evaluated overall tolerance on a 4-point scale.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18 years old or older
- Phototype greater than I
- Facial inflammatory acne with 15-50 inflammatory lesions and less than 50
non-inflammatory lesions (excluding the nasal pyramid)
- Did not receive a topical acne treatment in the last 15 days
- Did not receive cyclins or zinc-based treatment in the last month
- Did not take Diane-35 in the last 2 months. Current use of oral contraceptives is
acceptable if the subject is on a stable dose for at least six months prior Day 0.
- Did not take oral isotretinoin for the last 12 months
- Did not change their cosmetic habits in the last 15 days (ex: shaving cream)
- Agree to participate to the entire study
Exclusion Criteria:
- Less than 18 years old
- Phototype I
- With less than 15 or more than 50 inflammatory lesions on the face (excluding the
nasal pyramid)
- With more than 50 non-inflammatory lesions on the face (excluding the nasal pyramid)
- Have taken 1) A topical acne treatment in the last 15 days, or 2) Cyclins or
zinc-based treatment in the last month or 3) Oral isotretinoin in the last 12 months
- Woman: 1) Taking Diane-35, or 2) Taking an oral contraceptive for less than 6 months
or 3) That are pregnant or 4) That are nursing or 5) Not using any efficient
contraception method (if necessary)
- With a history of allergic reaction or hypersensitivity to one of the constituents of
the study product
- With peroxide sensitivity
- With history of photosensitivity
- With history of major medical or psychiatric condition or surgical interventions
that, in the opinion of the investigator, might put the subject at risk
- With an acute or chronic disease that could interfere with study results
- Susceptible to take a corticosteroid treatment during the study except inhaled or
topic when needed to treat a condition outside the face
- With a dermatologic condition on the face other than acne that might put the subject
at risk or interfere with study evaluations
- Using another cosmetic product than the one received for this study. Sunscreens are
allowed occasionally.
- Subject who must have extensive sun or ultra-violet exposure
Locations and Contacts
Innovaderm Research, Laval, Quebec, Canada
Innovaderm Research, Montreal, Quebec, Canada
Additional Information
Starting date: January 2006
Last updated: September 18, 2011
|